Wordt geladen...
Clinical and comparative utility of afatinib in non-small cell lung cancer
The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. However, all patients deve...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003149/ https://ncbi.nlm.nih.gov/pubmed/24790411 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S40567 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|